TB-500 typical research dosing
Across the available literature, TB-500 is most commonly administered at 2000–5000 mcg per dose, 1 time(s) per day, via subcutaneous injection. Research protocols frequently use a loading phase of 2–5 mg, 2× per week for 4–6 weeks, followed by a maintenance phase.
TB-500 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 5 mg TB-500 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 2000 mcg | 3500 mcg | 5000 mcg |
|---|---|---|---|---|
| 1 mL | 5000 mcg/mL | 40.0 units | 70.0 units | 100.0 units |
| 2 mL | 2500 mcg/mL | 80.0 units | 140.0 units | 200.0 units |
| 3 mL | 1667 mcg/mL | 120.0 units | 210.0 units | 300.0 units |
| 5 mL | 1000 mcg/mL | 200.0 units | 350.0 units | 500.0 units |
TB-500 cycle length
Most reported TB-500 protocols run 6 weeks on, then 4 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
TB-500 half-life and timing
TB-500 has a half-life of approximately 60 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.